A unique model
IRIC, located in the heart of the Université de Montréal campus, operates according to a unique model in Canada that combines, under one roof, fundamental research activities, a university-level training program and a research maturation team. These generate discoveries that advance knowledge or that can quickly translate into new therapeutic solutions.
-
![]()
News Meet Doris Alexandra Schuetz, Principal Research Advisor, Drug Discovery Unit
Doris Alexandra Schuetz is an inspiration to many members of the IRIC community. A committed professional dedicated to the fight against cancer on a daily basis, Doris also excels at running, a sport she has been practising for several years now. Eager to combine business with pleasure, Doris has raised close to $5,000 for cancer research at IRIC since 2022, through her participation in the Montreal Beneva Marathon. IRIC is proud to introduce you to this inspiring person.
-
![]()
News BRAF mutants escape stopped by therapeutic “agents”
The team led by Marc Therrien, CEO and Director of IRIC’s Intracellular Signaling Research Unit, has identified major structural changes that enable the BRAF protein to escape control and mimic its activation, giving it strong oncogenic potential. What’s more, the researchers succeeded in completely restoring the protein’s normal conformational state using small molecules – a breakthrough. The study, published in the prestigious journal Science, is the joint work of Hugo Lavoie (Associate Director), Ting Jin (Research Advisor) and Driss Lajoie (Research Advisor), who are the co-first authors. It is part of a close collaboration between several research teams which, in addition to the Therrien laboratory, involves teams from NYU Langone (New York), Université de Bordeaux and the University of Calgary.
-
![]()
News Next Generation Competition Program scholarship recipients arrive at the Institute
This summer, 10 students have the opportunity to complete a 12- or 16-week research internship at IRIC, in addition to benefiting from a scholarship of excellence.
-
![]()
News Jean-Coutu and Marcelle-Coutu pavilions: 20 years ago, a dream came true
On April 26, 2005, the two pavilions were inaugurated to house the Université de Montréal’s Faculty of Pharmacy and Institute for Research in Immunology and Cancer (IRIC), respectively.
-
![]()
News A total envelope of $612,610 for a project led by Sylvain Meloche, with support from IRIC, Immune Biosolutions and the SRC
In early 2025, Quebec’s Ministère de l’Économie, de l’Innovation et de l’Énergie (MEIE) awarded $475,000 in funding to Sylvain Meloche’s team, which heads IRIC’s Signalling and Cell Growth Research Unit. Axelys supported the team in the preparation of this funding application under the Programme de Maturation technologique (PSOv2d). This funding leverages additional private funding from Immune Biosolutions and the Société de Recherche sur le Cancer (SRC) respectively.
-
![]()
News IRIC Gala Audace: $1,060,025 raised for cancer research
On April 9, the 2025 edition of the Gala Audace of the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal was held. Thanks to the generosity of over 300 guests at the Marché Bonsecours, our valued donors and sponsors, a total of $1,060,025 was raised to support cancer research at IRIC.
-
![]()
News Manipulating the very small at large scale
The team led by Delphine Bouilly, director of IRIC’s Electronic Nanobiosensor Design and Application Research Unit, has developed an original technique for manipulating and moving graphene, a one-atom-thick material involved in the assembly of electronic chips, for applications in molecular diagnostics. Led by doctoral student Amira Bencherif, the study was published in the journal npj 2D materials and applications.
Upcoming events
-
February 15, 2024—August 31, 2025 Université de Montréal launches “L’heure est brave” campaign
To meet the major challenges of our time, the Université de Montréal is launching the “L’heure est brave” campaign. By contributing, you will help the University to develop the potential of its students, innovate for the common good, look after the health of living beings and improve the daily lives of communities. Your donations can make a difference. Let’s join forces to build tomorrow’s world.
Latest publications
See all publications-
April 28, 2025 DDB1 engagement defines the selectivity of S656 analogs for cyclin K degradation over CDK inhibition.
Moison C, Mendoza-Sanchez R, Gracias D, Schuetz DA, Spinella JF, Girard S, Thavonekham B, Chagraoui J, Durand A, Fortier S, MacRae T, Bonneil E, Rose Y, Mayotte N, Boivin I, Thibault P, Hébert J, Ruel R, Marinier A, Sauvageau G
EMBO Rep 2025-04-28 ; - See all publications